• Guidance for FY24 revenue of $500M+ and EBITDA to match FY23 (which was $38.2M) is unchanged. Argonaut current FY24 forecasts in line with revenue $515M and EBITDA $38.0M.
• EBITDA of $17.1M was 5% below out thinking but reiteration of full year guidance implies 2H24 EBITDA of $21 m or 23% above the 1H on a stronger margin
• Balance sheet remains solid and supports inorganic growth opportunities
• Long-term outlook very positive
Market did not like it, but seems ok to me.
- Forums
- ASX - By Stock
- Ann: Half Year Results Announcement
• Guidance for FY24 revenue of $500M+ and EBITDA to match FY23...
- There are more pages in this discussion • 9 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add SXE (ASX) to my watchlist
(20min delay)
|
|||||
Last
$1.48 |
Change
0.255(20.8%) |
Mkt cap ! $386.9M |
Open | High | Low | Value | Volume |
$1.50 | $1.51 | $1.41 | $4.885M | 3.325M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
3 | 21500 | $1.46 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.48 | 56532 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
3 | 21500 | 1.460 |
2 | 9822 | 1.455 |
3 | 58202 | 1.450 |
5 | 40354 | 1.440 |
1 | 2702 | 1.435 |
Price($) | Vol. | No. |
---|---|---|
1.480 | 56532 | 2 |
1.485 | 4709 | 2 |
1.490 | 30965 | 6 |
1.495 | 53702 | 3 |
1.500 | 26212 | 6 |
Last trade - 16.10pm 06/05/2024 (20 minute delay) ? |
|
|||||
Last
$1.48 |
  |
Change
0.255 ( 19.4 %) |
|||
Open | High | Low | Volume | ||
$1.55 | $1.55 | $1.43 | 385560 | ||
Last updated 15.58pm 06/05/2024 ? |
Featured News
SXE (ASX) Chart |
The Watchlist
ACW
ACTINOGEN MEDICAL LIMITED
Steven Gourlay, CEO
Steven Gourlay
CEO
Previous Video
Next Video
SPONSORED BY The Market Online